{"id":"rmenb-omv-nz-vaccine","safety":{"commonSideEffects":[{"rate":"50–70","effect":"Injection site pain"},{"rate":"30–50","effect":"Injection site erythema"},{"rate":"20–40","effect":"Injection site swelling"},{"rate":"30–50","effect":"Myalgia"},{"rate":"30–50","effect":"Fatigue"},{"rate":"20–40","effect":"Headache"},{"rate":"10–30","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rMenB+OMV NZ contains recombinant meningococcal proteins (rMenB) combined with outer membrane vesicles (OMV) derived from a New Zealand epidemic strain of N. meningitidis serogroup B. The vaccine elicits both humoral and cellular immune responses, generating bactericidal antibodies that target surface antigens of serogroup B meningococci, thereby providing protection against invasive meningococcal disease.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:35.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B"}]},"trialDetails":[{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06995430","phase":"PHASE3","title":"A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-07","conditions":"Meningitis","enrollment":226},{"nctId":"NCT06113198","phase":"PHASE4","title":"A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-11-10","conditions":"Meningitis, Meningococcal","enrollment":50},{"nctId":"NCT06446752","phase":"PHASE3","title":"BIYELA - Bexsero Immunisation in Young Women in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-08-14","conditions":"Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus","enrollment":1100},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT03587207","phase":"PHASE2","title":"Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-09","conditions":"Meningitis, Meningococcal","enrollment":520},{"nctId":"NCT00661713","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Meningococcal Disease","enrollment":1631},{"nctId":"NCT02446743","phase":"PHASE3","title":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-17","conditions":"Infections, Meningococcal","enrollment":531},{"nctId":"NCT01027351","phase":"PHASE2","title":"Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Meningococcal Disease","enrollment":163},{"nctId":"NCT02106390","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-05","conditions":"Infections, Meningococcal","enrollment":750},{"nctId":"NCT01148524","phase":"PHASE2, PHASE3","title":"Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-08","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":817},{"nctId":"NCT00657709","phase":"PHASE3","title":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Serogroup B Meningococcal Meningitis","enrollment":3630},{"nctId":"NCT00944034","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1588},{"nctId":"NCT01911221","phase":"PHASE3","title":"A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-08","conditions":"Prevention of the Meningococcal Disease","enrollment":13},{"nctId":"NCT01339923","phase":"PHASE3","title":"A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1409},{"nctId":"NCT01214850","phase":"PHASE3","title":"Novartis Vaccine and Diagnostics Carriage Trial","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"N. Meningitidis Carriage","enrollment":2968},{"nctId":"NCT02305446","phase":"PHASE3","title":"Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-12","conditions":"Meningitis, Meningococcal, Serogroup B","enrollment":55},{"nctId":"NCT01973218","phase":"PHASE3","title":"Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":264},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT01139021","phase":"PHASE3","title":"One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Meningococcal Disease","enrollment":508},{"nctId":"NCT01478347","phase":"PHASE3","title":"A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":18},{"nctId":"NCT00721396","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":1885},{"nctId":"NCT00433914","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-02","conditions":"Meningococcal Disease","enrollment":60},{"nctId":"NCT00847145","phase":"PHASE3","title":"Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Disease","enrollment":2249},{"nctId":"NCT01423084","phase":"PHASE3","title":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":344},{"nctId":"NCT01717638","phase":"PHASE3","title":"Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":805},{"nctId":"NCT01026974","phase":"PHASE2","title":"Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-02","conditions":"Meningococcal Disease","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bexsero"],"phase":"marketed","status":"active","brandName":"rMenB+OMV NZ vaccine","genericName":"rMenB+OMV NZ vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}